Literature DB >> 15234212

Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats.

Jason P Hodde1, Mark A Suckow, William R Wolter, Michael C Hiles.   

Abstract

BACKGROUND: Site-specific remodeling and angiogenesis are two observations associated with the use of small intestinal submucosa (SIS) as a tissue repair graft. Its angiogenic capacity has raised questions concerning its effect on tumor growth and metastasis in clinical tumor resection cases. The effect of SIS on the ability of neoplastic (prostate adenocarcinoma) cells to establish, grow, and metastasize was examined in Lobund-Wistar (L-W) rats.
MATERIALS AND METHODS: In one study, SIS, expanded polytetrafluoroethylene (ePTFE), or human cadaveric dermis was placed in a subcutaneous pocket on the flank of L-W rats and immediately inoculated with PA-III cell suspension. Tumors were allowed to establish and metastasize for 5 weeks prior to sacrifice. Rate of tumor growth, tumor weight, and frequency of lung metastases were assessed. In a second study, SIS was placed in a resected tumor bed and tumors were allowed to recur. Rate of tumor growth, tumor weight, and frequency of lung metastases were assessed after 3 weeks.
RESULTS: ePTFE hastened the rate of formation of palpable tumors compared to controls and other materials; cadaveric dermis and SIS did not. No differences between materials were noted in final tumor weight nor in the frequency of metastasis to the lungs. Following surgical tumor resection, residual tumor cells led to recurrence of same-site tumors in all animals, but in the defects augmented with SIS, the tumors were significantly smaller than those which regrew in the resected, unaugmented group.
CONCLUSIONS: This study demonstrates that SIS does not enhance tumor establishment, growth, or metastasis in de novo tumors. Furthermore, SIS appears to reduce the rate of tumor growth, but not metastasis, when applied in direct contact with a residual tumor bed in a rat model of prostate-related tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234212     DOI: 10.1016/j.jss.2003.10.022

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP1-17.

Authors:  J S Frieling; G Shay; V Izumi; S T Aherne; R G Saul; M Budzevich; J Koomen; C C Lynch
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

2.  A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy.

Authors:  Matthew T Wolf; Sudipto Ganguly; Tony L Wang; Christopher W Anderson; Kaitlyn Sadtler; Radhika Narain; Christopher Cherry; Alexis J Parrillo; Benjamin V Park; Guannan Wang; Fan Pan; Saraswati Sukumar; Drew M Pardoll; Jennifer H Elisseeff
Journal:  Sci Transl Med       Date:  2019-01-30       Impact factor: 17.956

3.  Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype.

Authors:  Lindsey T Saldin; Shil Patel; Li Zhang; Luai Huleihel; George S Hussey; David G Nascari; Lina M Quijano; Xue Li; Divya Raghu; Anant K Bajwa; Nicholas G Smith; Christopher C Chung; Ashten N Omstead; Juliann E Kosovec; Blair A Jobe; Neill J Turner; Ali H Zaidi; Stephen F Badylak
Journal:  Tissue Eng Part A       Date:  2019-03       Impact factor: 3.845

4.  Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.

Authors:  Leah M Cook; Arturo Araujo; Julio M Pow-Sang; Mikalai M Budzevich; David Basanta; Conor C Lynch
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

5.  Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.

Authors:  Jeremy J McGuire; Jeremy S Frieling; Chen Hao Lo; Tao Li; Ayaz Muhammad; Harshani R Lawrence; Nicholas J Lawrence; Leah M Cook; Conor C Lynch
Journal:  Nat Commun       Date:  2021-02-01       Impact factor: 17.694

6.  A liquid fraction of extracellular matrix inhibits glioma cell viability in vitro and in vivo.

Authors:  Mark H Murdock; George S Hussey; Jordan T Chang; Ryan C Hill; David G Nascari; Aparna V Rao; Kirk C Hansen; Lesley M Foley; T Kevin Hitchens; Nduka M Amankulor; Stephen F Badylak
Journal:  Oncotarget       Date:  2022-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.